IXICO PLC (IXI) - Total Assets
Based on the latest financial reports, IXICO PLC (IXI) holds total assets worth GBX13.84 Million GBX (≈ $1.68K USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of IXICO PLC for net asset value and shareholders' equity analysis.
IXICO PLC - Total Assets Trend (1993–2025)
This chart illustrates how IXICO PLC's total assets have evolved over time, based on quarterly financial data.
IXICO PLC - Asset Composition Analysis
Current Asset Composition (September 2025)
IXICO PLC's total assets of GBX13.84 Million consist of 45.1% current assets and 55.0% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 25.6% |
| Accounts Receivable | GBX2.70 Million | 19.5% |
| Inventory | GBX0.00 | 0.0% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX7.18 Million | 51.9% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (1993–2025)
This chart illustrates how IXICO PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see IXI market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: IXICO PLC's current assets represent 45.1% of total assets in 2025, a decrease from 79.5% in 1993.
- Cash Position: Cash and equivalents constituted 25.6% of total assets in 2025, up from 15.7% in 1993.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 51.0% of total assets, an increase from 0.0% in 1993.
- Asset Diversification: The largest asset category is intangible assets at 51.9% of total assets.
IXICO PLC Competitors by Total Assets
Key competitors of IXICO PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
IXICO PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.03 | 2.85 | 3.85 |
| Quick Ratio | 3.03 | 2.85 | 3.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX4.18 Million | GBX2.92 Million | GBX7.61 Million |
IXICO PLC - Advanced Valuation Insights
This section examines the relationship between IXICO PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.69 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 23.7% |
| Total Assets | GBX13.84 Million |
| Market Capitalization | $77.52K USD |
Valuation Analysis
Below Book Valuation: The market values IXICO PLC's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: IXICO PLC's assets grew by 23.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for IXICO PLC (1993–2025)
The table below shows the annual total assets of IXICO PLC from 1993 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | GBX13.84 Million ≈ $1.68K |
+23.70% |
| 2024-09-30 | GBX11.19 Million ≈ $1.36K |
-13.87% |
| 2023-09-30 | GBX12.99 Million ≈ $1.58K |
-11.36% |
| 2022-09-30 | GBX14.65 Million ≈ $1.78K |
+2.77% |
| 2021-09-30 | GBX14.26 Million ≈ $1.74K |
+17.89% |
| 2020-09-30 | GBX12.10 Million ≈ $1.47K |
+13.04% |
| 2019-09-30 | GBX10.70 Million ≈ $1.30K |
+3.50% |
| 2018-09-30 | GBX10.34 Million ≈ $1.26K |
+129.30% |
| 2017-09-30 | GBX4.51 Million ≈ $548.61 |
-20.64% |
| 2016-09-30 | GBX5.68 Million ≈ $691.34 |
+34.04% |
| 2015-09-30 | GBX4.24 Million ≈ $515.76 |
-21.69% |
| 2014-09-30 | GBX5.41 Million ≈ $658.61 |
+5.05% |
| 2013-09-30 | GBX5.15 Million ≈ $626.97 |
-51.34% |
| 2012-09-30 | GBX10.59 Million ≈ $1.29K |
-43.06% |
| 2011-09-30 | GBX18.60 Million ≈ $2.26K |
-24.44% |
| 2010-09-30 | GBX24.61 Million ≈ $2.99K |
+404.05% |
| 2009-09-30 | GBX4.88 Million ≈ $594.12 |
-42.51% |
| 2008-09-30 | GBX8.49 Million ≈ $1.03K |
+104.48% |
| 2007-09-30 | GBX4.15 Million ≈ $505.42 |
-49.44% |
| 2006-08-31 | GBX8.22 Million ≈ $999.65 |
-41.62% |
| 2005-08-31 | GBX14.07 Million ≈ $1.71K |
+86.37% |
| 2004-08-31 | GBX7.55 Million ≈ $918.74 |
+9.24% |
| 2003-08-31 | GBX6.91 Million ≈ $840.99 |
-43.52% |
| 2002-08-31 | GBX12.24 Million ≈ $1.49K |
-13.62% |
| 2001-08-31 | GBX14.17 Million ≈ $1.72K |
+148.15% |
| 2000-08-31 | GBX5.71 Million ≈ $694.62 |
+78.46% |
| 1999-08-31 | GBX3.20 Million ≈ $389.23 |
-14.12% |
| 1998-08-31 | GBX3.73 Million ≈ $453.22 |
-48.54% |
| 1997-08-31 | GBX7.24 Million ≈ $880.66 |
-27.15% |
| 1996-08-31 | GBX9.94 Million ≈ $1.21K |
+2830.68% |
| 1995-08-31 | GBX339.00K ≈ $41.25 |
+80.32% |
| 1994-08-31 | GBX188.00K ≈ $22.87 |
-58.50% |
| 1993-08-31 | GBX453.00K ≈ $55.12 |
-- |
About IXICO PLC
IXICO plc provides data analytics services to biopharmaceutical industry in the United States, the United Kingdom, the Netherlands, Denmark, Switzerland, Ireland, Europe, and internationally. The company offers collection, analysis, management, and reporting on gathered clinical study data; neurological diseases data collection and analysis; and sales and marketing services. It also provides imag… Read more